Jubilant Ingrevia Q2 FY27 Results: Key Date and Outlook

Board meeting scheduled for October 27

Jubilant Ingrevia Limited is scheduled to consider and approve its unaudited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2026. The board meeting is set for Tuesday, October 27, 2026. The company has said the results will also be made available on its corporate website. The announcement places Jubilant Ingrevia among companies scheduled to report second-quarter FY27 numbers on the day. Capri Global Capital, Honeywell Automation India, IndiaMART InterMESH, Indus Towers, JSW Infrastructure, JSW Cement, Gravita India, Syngene International and Tata Capital are also listed among companies expected to announce results.

Q1 FY27 set a higher base

The latest reported quarterly figures provide the immediate operating context ahead of the board meeting. Jubilant Ingrevia reported revenue of Rs 1,300 crore in Q1 FY27, up 25.3% year on year and 10.3% sequentially. Net profit was Rs 106 crore, rising 40.9% from a year earlier. The reported operating margin for the quarter was 15.3%. Revenue of Rs 1,300 crore was described as a 15-quarter high in the supplied company-related information.

A separate earnings summary stated that first-quarter revenue was Rs 1,310 crore, up 26% year on year, while net income was Rs 106 crore. That summary put profit margin at 8.1%, compared with 7.2% in the corresponding earlier period. It also said revenue exceeded analyst estimates by 3.0%, while earnings per share missed estimates by 1.8%. The differing revenue presentation of Rs 1,300 crore and Rs 1,310 crore should be read in the context of the separate source summaries provided.

What the October results cover

The scheduled results relate to the July-September 2026 quarter and the first half of FY27. The board will consider both standalone and consolidated statements. The formal announcement is significant because it will show whether the growth seen in the June quarter continued through the next reporting period. It will also provide updated information on profitability and management commentary after the first-half period.

No Q2 FY27 revenue, profit or margin figure has been provided before the board meeting. Therefore, the scheduled event should not be treated as a release of already confirmed quarterly financial performance. The available information only confirms the meeting date, the financial period under review and the Q1 FY27 numbers reported previously.

FY27 EBITDA guidance remains a key reference

Management had guided for FY27 EBITDA at the upper end of a Rs 750 crore to Rs 800 crore range, compared with about Rs 600 crore in FY26. In the July 1, 2026 update cited in the material, Anand Rathi Research interpreted this as operating EBITDA of about Rs 760 crore. That was above the broker's estimate of about Rs 730 crore. The guidance provides a full-year benchmark against which investors may assess the first-half operating performance.

The research update maintained a Buy recommendation following a visit to the Bharuch manufacturing site. Its assessment identified CDMO ramp-up, a better product mix in Nutrition and Health Solutions, and operating leverage from newly commissioned assets as factors behind its FY27 earnings-inflection view. These are research views and management guidance, rather than confirmed Q2 outcomes. The October announcement may provide updated operational commentary on these areas.

CDMO and specialty chemicals in focus

The supplied information says confirmed CDMO molecules rose to 25, including five new additions. It also states that specialty chemicals EBITDA margin held at 26%, supported by more than 95% pyridine utilisation and growth in captive consumption. These operating details are relevant because the brokerage expects CDMO and the Nutrition and Health Solutions business to be important contributors to incremental EBITDA.

Anand Rathi expects Specialty Chemicals and Nutrition and Health Solutions to account for more than 85% of incremental EBITDA over FY26 to FY28E. The broker also expects CDMO revenue to scale to about Rs 1,200 crore by FY28E. These are forward estimates from the brokerage, not company-reported revenue for the current quarter. Their relevance to Q2 will depend on any disclosures made with the results.

Financial estimates from the research update

The brokerage's projections point to an expansion in revenue and operating profitability over the FY26-FY28E period. Its revenue estimate rises from Rs 4,390 crore in FY26 to Rs 5,490 crore in FY27E and Rs 6,320 crore in FY28E. EBITDA is estimated to increase from Rs 570 crore to Rs 730 crore and then Rs 930 crore. The projected EBITDA margin rises from 12.9% in FY26 to 13.4% in FY27E and 14.7% in FY28E.

Comparison with the previous second quarter

Jubilant Ingrevia's Q2 FY26 revenue was reported at Rs 1,121 crore, up 8% year on year. EBITDA was reported at Rs 146 crore, while profit after tax was Rs 70 crore, up 18% year on year. The company described that revenue level as its highest quarterly revenue in 10 quarters at the time. These historical figures offer a comparison point, but they do not indicate the yet-to-be-announced Q2 FY27 performance.

The Q1 FY27 revenue figure of Rs 1,300 crore was above the reported Q2 FY26 revenue of Rs 1,121 crore. However, the two quarters relate to different periods and business conditions. Investors typically use the forthcoming result to assess year-on-year and sequential changes once the company releases the complete financial statements.

Market relevance of the result

The result matters because it will update the market on the company's progress toward its stated FY27 EBITDA range. Revenue growth, EBITDA margins, net profit and segment-level commentary will be central measures in assessing the first half. Information on CDMO additions, utilisation and the Nutrition and Health Solutions mix may also be relevant to the assumptions in the brokerage's FY27E and FY28E estimates.

The broader chemicals sector comparison cited in the material is also notable. The earnings summary said Jubilant Ingrevia's revenue was forecast to grow at an average 13% annually over the following three years, compared with a 12% forecast for the Indian chemicals industry. This is a forecast and not a reported growth outcome. The company’s October disclosure will provide a fresh reported data point against its own operating targets and market expectations.

What to watch in the release

The confirmed next step is the board meeting on October 27, 2026, to consider the Q2 FY27 and half-year results. Investors will have access to the unaudited standalone and consolidated statements after the company makes them available. Until then, Q1 FY27 revenue of Rs 1,300 crore, net profit of Rs 106 crore and the FY27 EBITDA guidance range remain the principal figures available in the supplied material.

Jubilant Ingrevia's upcoming disclosure will clarify how the July-September quarter contributed to the first half of FY27. It will also show whether the company has provided any revised outlook or operational update on its CDMO, specialty chemicals, and Nutrition and Health Solutions businesses. The board meeting date is confirmed, while the Q2 financial numbers remain pending.